Sam Brusco, Associate Editor12.13.23
electroCore has been issued a new patent from the USPTO that covers a system to stimulate a nerve target in the neck or head to treat various disorders, like primary headache.
U.S. Patent No. 11,839,764 is entitled “Systems and Methods for Treating a Medical Condition with an Electrical Stimulation Treatment Regimen.” It was issued on December 12 and is “generally related to a system including a downloadable software program on, for example, a mobile device, that is configured to control a parameter of the electrical impulses delivered by a stimulator for targeting nerves in the head or neck of a patient to treat various disorders such as primary headache, among others.”
“We continue to grow our intellectual property portfolio,” said electroCore’s chief strategy officer Joshua Lev. “This new patent strengthens our position around systems that utilize mobile applications to control stimulators that treat various disorders such as primary headache, which may be useful as we develop our next generation application enabled products and devices.”
Earlier this year, the company was awarded three new patents for its non-invasive vagus nerve stimulation (nVNS) technology and methods to treat addiction.
In September, electroCore began an agreement to distribute Reliefband Technologies' Reletex within the U.S. Department of Veterans Affairs (VA) and other federal supply schedule (FSS) eligible entities.
U.S. Patent No. 11,839,764 is entitled “Systems and Methods for Treating a Medical Condition with an Electrical Stimulation Treatment Regimen.” It was issued on December 12 and is “generally related to a system including a downloadable software program on, for example, a mobile device, that is configured to control a parameter of the electrical impulses delivered by a stimulator for targeting nerves in the head or neck of a patient to treat various disorders such as primary headache, among others.”
“We continue to grow our intellectual property portfolio,” said electroCore’s chief strategy officer Joshua Lev. “This new patent strengthens our position around systems that utilize mobile applications to control stimulators that treat various disorders such as primary headache, which may be useful as we develop our next generation application enabled products and devices.”
Earlier this year, the company was awarded three new patents for its non-invasive vagus nerve stimulation (nVNS) technology and methods to treat addiction.
In September, electroCore began an agreement to distribute Reliefband Technologies' Reletex within the U.S. Department of Veterans Affairs (VA) and other federal supply schedule (FSS) eligible entities.